Skip to main content
Top
Published in: BMC Gastroenterology 1/2014

Open Access 01-12-2014 | Research article

Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn’s disease

Authors: Darina Kohoutova, Marcela Drahosova, Paula Moravkova, Stanislav Rejchrt, Jan Bures

Published in: BMC Gastroenterology | Issue 1/2014

Login to get access

Abstract

Background

Precise diagnostics of inflammatory bowel disease (IBD) and identification of potentially more aggressive phenotypes of Crohn’s disease (CD) is urgently needed. The aim of our prospective study was to assess the relationship between serum anti-OmpC IgA (Outer membrane protein C), anti-GP2 (anti-glycoprotein 2) IgG and anti-GP2 IgA antibodies with IBD and their association with complicated forms of CD.

Methods

The study included 86 patients with CD, 25 patients with UC and 45 controls, blood donors. In CD group, 24/86 (28%) had B1 phenotype, 20/86 (23%) B2, 13/86 (15%) B3 and 29/86 (34%) B2 + B3. L1 involvement was present in 13/86 (15%), L2 in 13/86 (15%), L3 in 60/86 (70%). Serum anti-OmpC IgA, anti-GP2 IgG and IgA antibodies were investigated by means of ELISA. The data obtained were tested statistically by means of descriptive statistics, non-paired t-test, Mann-Whitney rank sum test, Spearman rank order correlation and Pearson product moment correlation using SigmaStat software.

Results

Anti-OmpC IgA were noted to be significantly higher in CD (median 32.6, inter-quartile range (IQR) 18.9-60.7) compared to the controls (median 18.3, IQR 11.1-23.1), p < 0.001. Anti-GP2 IgG were significantly higher in CD (median 13.9, IQR 8.6-25.6) compared to the controls (median 8.0, IQR 4.7-10.8), p < 0.001. Anti-GP2 IgA were significantly higher in CD (median 20.1, IQR 9.1-40.4) compared to the controls (median 9.8, IQR 5.6-16.9), p < 0.001. Significant difference was found in anti-OmpC IgA between UC (median 26.2, IQR 20.2-36.4) and the controls (median 18.3, IQR 11.1-23.1), p < 0.001. In CD anti-OmpC IgA were significantly higher in B2 compared to B1: p = 0.041 and in B2 + B3 compared to B1: p = 0.036. Anti-GP2 IgA were significantly higher in B2 + B3 compared to B1: p = 0.009 and in B3 compared to B1: p = 0.029. In CD there was a significant difference in anti-OmpC IgA between patients with surgery and without surgery, p = 0.005.

Conclusions

We have confirmed association between anti-OmpC IgA and IBD (CD and UC) and an association between anti-GP2 (IgG and IgA) and CD. Patients with complicated forms of CD have significantly higher levels of anti-OmpC IgA and anti-GP2 IgA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B, Ibsen Study Group: Clinical course in Crohn’s disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007, 42: 602-610. 10.1080/00365520601076124.CrossRefPubMed Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B, Ibsen Study Group: Clinical course in Crohn’s disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007, 42: 602-610. 10.1080/00365520601076124.CrossRefPubMed
2.
go back to reference Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005, 19 (Suppl A): 5A-36A.CrossRefPubMed Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005, 19 (Suppl A): 5A-36A.CrossRefPubMed
3.
go back to reference Loly C, Belaiche J, Louis E: Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008, 43: 948-954. 10.1080/00365520801957149.CrossRefPubMed Loly C, Belaiche J, Louis E: Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008, 43: 948-954. 10.1080/00365520801957149.CrossRefPubMed
4.
go back to reference Odes S, Vardi H, Friger M, Wolters F, Hoie O, Moum B, Bernklev T, Yona H, Russel M, Munkholm P, Langholz E, Riis L, Politi P, Bondini P, Tsianos E, Katsanos K, Clofent J, Vermeire S, Freitas J, Mouzas I, Limonard C, O’Morain C, Monteiro E, Fornaciari G, Vatn M, Stockbrugger R, European Collaborative Study Group on Inflammatory Bowel Disease: Effect of phenotype on health care costs in Crohn’s disease: a European study using the Montreal classification. J Crohns Colitis. 2007, 1: 87-96. 10.1016/j.crohns.2007.08.004.CrossRefPubMed Odes S, Vardi H, Friger M, Wolters F, Hoie O, Moum B, Bernklev T, Yona H, Russel M, Munkholm P, Langholz E, Riis L, Politi P, Bondini P, Tsianos E, Katsanos K, Clofent J, Vermeire S, Freitas J, Mouzas I, Limonard C, O’Morain C, Monteiro E, Fornaciari G, Vatn M, Stockbrugger R, European Collaborative Study Group on Inflammatory Bowel Disease: Effect of phenotype on health care costs in Crohn’s disease: a European study using the Montreal classification. J Crohns Colitis. 2007, 1: 87-96. 10.1016/j.crohns.2007.08.004.CrossRefPubMed
5.
go back to reference Dotan I: Disease behavior in adult patients: are there predictors for stricture or fistula formation?. Dig Dis. 2009, 27: 206-211. 10.1159/000228551.CrossRefPubMed Dotan I: Disease behavior in adult patients: are there predictors for stricture or fistula formation?. Dig Dis. 2009, 27: 206-211. 10.1159/000228551.CrossRefPubMed
6.
go back to reference Swidsinski A, Loening-Baucke V, Herber A: Mucosal flora in Crohn’s disease and ulcerative colitis - an overview. J Physiol Pharmacol. 2009, 60 (Suppl 6): 61-71.PubMed Swidsinski A, Loening-Baucke V, Herber A: Mucosal flora in Crohn’s disease and ulcerative colitis - an overview. J Physiol Pharmacol. 2009, 60 (Suppl 6): 61-71.PubMed
7.
go back to reference Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S: Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006, 55: 1760-1767. 10.1136/gut.2005.078824.CrossRefPubMedPubMedCentral Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S: Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006, 55: 1760-1767. 10.1136/gut.2005.078824.CrossRefPubMedPubMedCentral
8.
go back to reference Gologan S, Iacob R, Preda C, Vadan R, Cotruta B, Catuneanu AM, Iacob S, Constantinescu I, Gheorghe L, Iobagiu S, Gheorghe C, Diculescu M: Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more aggressive phenotypes in Romanian patients with Crohn’s disease. J Gastrointestin Liver Dis. 2012, 21: 39-44.PubMed Gologan S, Iacob R, Preda C, Vadan R, Cotruta B, Catuneanu AM, Iacob S, Constantinescu I, Gheorghe L, Iobagiu S, Gheorghe C, Diculescu M: Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more aggressive phenotypes in Romanian patients with Crohn’s disease. J Gastrointestin Liver Dis. 2012, 21: 39-44.PubMed
9.
go back to reference Gupta N, Cohen SA, Bostrom AG, Kirschner BS, Baldassano RN, Winter HS, Ferry GD, Smith T, Abramson O, Gold BD, Heyman MB: Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology. 2006, 130: 1069-1077. 10.1053/j.gastro.2006.02.003.CrossRefPubMed Gupta N, Cohen SA, Bostrom AG, Kirschner BS, Baldassano RN, Winter HS, Ferry GD, Smith T, Abramson O, Gold BD, Heyman MB: Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology. 2006, 130: 1069-1077. 10.1053/j.gastro.2006.02.003.CrossRefPubMed
10.
go back to reference Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S: New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007, 56: 1394-403. 10.1136/gut.2006.108043.CrossRefPubMedPubMedCentral Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S: New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007, 56: 1394-403. 10.1136/gut.2006.108043.CrossRefPubMedPubMedCentral
11.
go back to reference Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J, Lakatos PL, Hungarian IBD Study Group: New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008, 103: 665-81. 10.1111/j.1572-0241.2007.01652.x.CrossRefPubMed Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J, Lakatos PL, Hungarian IBD Study Group: New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008, 103: 665-81. 10.1111/j.1572-0241.2007.01652.x.CrossRefPubMed
12.
go back to reference Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM: Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005, 128: 2020-2028. 10.1053/j.gastro.2005.03.046.CrossRefPubMed Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM: Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005, 128: 2020-2028. 10.1053/j.gastro.2005.03.046.CrossRefPubMed
13.
go back to reference Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR: Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004, 126: 414-424. 10.1053/j.gastro.2003.11.015.CrossRefPubMed Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR: Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004, 126: 414-424. 10.1053/j.gastro.2003.11.015.CrossRefPubMed
14.
go back to reference Bossuyt X: Serologic markers in inflammatory bowel disease. Clin Chem. 2006, 52: 171-181. 10.1373/clinchem.2005.058560.CrossRefPubMed Bossuyt X: Serologic markers in inflammatory bowel disease. Clin Chem. 2006, 52: 171-181. 10.1373/clinchem.2005.058560.CrossRefPubMed
15.
go back to reference Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J: Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004, 99: 2376-2384. 10.1111/j.1572-0241.2004.40417.x.CrossRefPubMed Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J: Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004, 99: 2376-2384. 10.1111/j.1572-0241.2004.40417.x.CrossRefPubMed
16.
go back to reference Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H, Western Regional Pediatric IBD Research Alliance: Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006, 101: 360-367. 10.1111/j.1572-0241.2006.00456.x.CrossRefPubMedPubMedCentral Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H, Western Regional Pediatric IBD Research Alliance: Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006, 101: 360-367. 10.1111/j.1572-0241.2006.00456.x.CrossRefPubMedPubMedCentral
18.
go back to reference Shen B: Bacteriology in the etiopathogenesis of pouchitis. Dig Dis. 2012, 30: 351-357. 10.1159/000338125.CrossRefPubMed Shen B: Bacteriology in the etiopathogenesis of pouchitis. Dig Dis. 2012, 30: 351-357. 10.1159/000338125.CrossRefPubMed
19.
go back to reference Kotlowski R, Bernstein CN, Sepehri S, Krause DO: High prevalence of Escherichia coli belonging to the B2 + D phylogenetic group in inflammatory bowel disease. Gut. 2007, 56: 669-675. 10.1136/gut.2006.099796.CrossRefPubMed Kotlowski R, Bernstein CN, Sepehri S, Krause DO: High prevalence of Escherichia coli belonging to the B2 + D phylogenetic group in inflammatory bowel disease. Gut. 2007, 56: 669-675. 10.1136/gut.2006.099796.CrossRefPubMed
20.
go back to reference Nikaido H: Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003, 67: 593-656. 10.1128/MMBR.67.4.593-656.2003.CrossRefPubMedPubMedCentral Nikaido H: Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003, 67: 593-656. 10.1128/MMBR.67.4.593-656.2003.CrossRefPubMedPubMedCentral
21.
go back to reference Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR: Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002, 123: 689-699. 10.1053/gast.2002.35379.CrossRefPubMed Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR: Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002, 123: 689-699. 10.1053/gast.2002.35379.CrossRefPubMed
22.
go back to reference Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A: Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004, 99: 2235-2241. 10.1111/j.1572-0241.2004.40369.x.CrossRefPubMed Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A: Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004, 99: 2235-2241. 10.1111/j.1572-0241.2004.40369.x.CrossRefPubMed
23.
go back to reference Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J: Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000, 68: 1542-1548. 10.1128/IAI.68.3.1542-1548.2000.CrossRefPubMedPubMedCentral Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J: Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000, 68: 1542-1548. 10.1128/IAI.68.3.1542-1548.2000.CrossRefPubMedPubMedCentral
24.
go back to reference Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004, 127: 412-421. 10.1053/j.gastro.2004.04.061.CrossRefPubMed Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004, 127: 412-421. 10.1053/j.gastro.2004.04.061.CrossRefPubMed
25.
go back to reference Knights D, Lassen KG, Xavier RJ: Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013, 62: 1505-10. 10.1136/gutjnl-2012-303954.CrossRefPubMed Knights D, Lassen KG, Xavier RJ: Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013, 62: 1505-10. 10.1136/gutjnl-2012-303954.CrossRefPubMed
26.
go back to reference Robles Alonso V, Guarner F: Linking the gut microbiota to human health. Br J Nutr. 2013, 109 (Suppl 2): 21-26. 10.1017/S0007114512005235.CrossRef Robles Alonso V, Guarner F: Linking the gut microbiota to human health. Br J Nutr. 2013, 109 (Suppl 2): 21-26. 10.1017/S0007114512005235.CrossRef
27.
go back to reference Manichanh C, Borruel N, Casellas F, Guarner F: The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012, 9: 599-608. 10.1038/nrgastro.2012.152.CrossRefPubMed Manichanh C, Borruel N, Casellas F, Guarner F: The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012, 9: 599-608. 10.1038/nrgastro.2012.152.CrossRefPubMed
28.
go back to reference Roggenbuck D, Reinhold D, Schierack P, Bogdanos DP, Conrad K, Laass MW: Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges. Clin Chem Lab Med. 2013, 14: 1-12. Roggenbuck D, Reinhold D, Schierack P, Bogdanos DP, Conrad K, Laass MW: Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges. Clin Chem Lab Med. 2013, 14: 1-12.
29.
go back to reference Roggenbuck D, Reinhold D, Werner L, Schierack P, Bogdanos DP, Conrad K: Glycoprotein 2 antibodies in Crohn’s disease. Adv Clin Chem. 2013, 60: 187-208. 10.1016/B978-0-12-407681-5.00006-4.CrossRefPubMed Roggenbuck D, Reinhold D, Werner L, Schierack P, Bogdanos DP, Conrad K: Glycoprotein 2 antibodies in Crohn’s disease. Adv Clin Chem. 2013, 60: 187-208. 10.1016/B978-0-12-407681-5.00006-4.CrossRefPubMed
30.
go back to reference Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, Porstmann T, Laass MW, Henker J, Büning C, Feist E, Conrad K: Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease. Gut. 2009, 58: 1620-1628. 10.1136/gut.2008.162495.CrossRefPubMed Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, Porstmann T, Laass MW, Henker J, Büning C, Feist E, Conrad K: Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease. Gut. 2009, 58: 1620-1628. 10.1136/gut.2008.162495.CrossRefPubMed
31.
go back to reference Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Barta Z, Stocker W, Papp J, Veres G, Papp M, Hungarian IBD Study Group: Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009, 15: 365-374. 10.1002/ibd.20778.CrossRefPubMed Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Barta Z, Stocker W, Papp J, Veres G, Papp M, Hungarian IBD Study Group: Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009, 15: 365-374. 10.1002/ibd.20778.CrossRefPubMed
32.
go back to reference Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pavlidis P, von Arnim U, Malfertheiner P, Forbes A, Conrad K, Laass MW: Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease. BMC Gastroenterol. 2012, 12: 102-10.1186/1471-230X-12-102.CrossRefPubMedPubMedCentral Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pavlidis P, von Arnim U, Malfertheiner P, Forbes A, Conrad K, Laass MW: Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease. BMC Gastroenterol. 2012, 12: 102-10.1186/1471-230X-12-102.CrossRefPubMedPubMedCentral
33.
go back to reference Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, Smyk DS, Koutsoumpas AL, Rigopoulou EI, Conrad K, Forbes A, Bogdanos DP: Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn’s disease. Clin Dev Immunol. 2012, 2012: 640835-10.1155/2012/640835.CrossRefPubMedPubMedCentral Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, Smyk DS, Koutsoumpas AL, Rigopoulou EI, Conrad K, Forbes A, Bogdanos DP: Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn’s disease. Clin Dev Immunol. 2012, 2012: 640835-10.1155/2012/640835.CrossRefPubMedPubMedCentral
Metadata
Title
Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn’s disease
Authors
Darina Kohoutova
Marcela Drahosova
Paula Moravkova
Stanislav Rejchrt
Jan Bures
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2014
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-014-0190-1

Other articles of this Issue 1/2014

BMC Gastroenterology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.